NHS England and NHS Improvement’s MedTech Funding Mandate (MTFM) Policy was published in January and is effective from 1 April 2021. This policy requires trusts to make four technologies available to patients: HeartFlow, Placental Growth Factor Based Testing, SecurAcath and gammaCore.
The KSS AHSN team and the technology suppliers are on hand to assist systems to access these technologies, which are supported by NICE guidance, deliver cost savings within 12 months, and reduce hospital visits and clinical interventions which is vital in the current COVID pandemic.
The MTFM will still apply from 1 April 2021
Where trusts have already implemented these technologies, providers and commissioners should work together to ensure a continuation of service to patients from 1 April 2021 and (once financial arrangements are confirmed) make such adjustment to contract values as may be necessary to support this.
Systems will be expected to fund these technologies from within the system funding envelopes allocated and from core allocations thereafter.
New site implementation will need to be managed alongside pandemic activity and recovery.
The Accelerated Access Collaborative (AAC) has also been working with Strategic Finance teams to provide further information to ensure that the NICE-approved technologies supported by the MedTech Funding Mandate policy continue to be made available from 1st April 2021 without disruption. A communication from the NHS England Chief Finance Officer has been sent to regional Directors of Finance, asking them to disseminate to organisations on behalf of NHS England and NHS Improvement.
Find out more
Please contact Dr. Charlotte Roberts, Senior Programme Manager at KSS AHSN, with any queries or requests for support with the MTFM.
